Abstract

Background

• 3D-EXplore technology allows for the ex vivo testing of different classes of immuno-oncology therapeutics for tumor cell killing and tumor-resident immune cell activation.
• Our proprietary processing method, which employs fresh patient derived
tumor tissue, results in the generation of 3D tumoroids that retain the
intact tumor microenvironment. This model allows for accurate
quantification of any antibody-drug conjugate (ADC) mediated changes
to the complex cell-to-cell interactions that may result in changes in
tumor cell viability and immune cell profile.
• We have developed a high content imaging approach using a fresh
patient 3D tumoroid model with intact tumor stroma for assessment
tumor cell killing.